Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FDEQ0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,591
Award facts
- Contract value 100% obligated
- $11,591.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $11,591.04 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/mL auto-injector medication. This delivery order, issued on January 15, 2026, with an ultimate completion date of January 16, 2026, carries a firm fixed-price structure with no set-aside designation, indicating the vendor's competitive capability in unrestricted federal procurement. The award was funded by the Defense Logistics Agency and represents a single transaction under the vendor's established pharmaceutical supply relationships with the federal government.
This delivery order operates under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide. The parent IDC, designated SPE2DR and awarded November 13, 2025, authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables. DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the federal military medical system, with demonstrated performance across diverse product categories including specialty biologics, oncology treatments, vaccines, and emergency medications, positioning the company as a key regional prime vendor contractor within the broader DoD pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FDEQ0?
SPE2DR26FDEQ0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FDEQ0 worth?
The government has obligated $11,591 on SPE2DR26FDEQ0.
Is contract SPE2DR26FDEQ0 an order under another contract?
Yes. SPE2DR26FDEQ0 is a delivery order under SPE2DR25D9112, an indefinite delivery contract.
Was contract SPE2DR26FDEQ0 competed?
The extent of competition for SPE2DR26FDEQ0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award